Related Experiment Video

Updated: Feb 8, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.9K

Inhibition of GSK3α/β impairs the progression of HNSCC

Lisa Schulz1, Ralph Pries1, Aruna Sree Lanka1

  • 1Department of Otorhinolaryngology, University of Luebeck, Luebeck 23538, Germany.

Oncotarget
|July 3, 2018
PubMed
Abstract

Insights

Glycogen synthase kinase 3 (GSK3) inhibition significantly reduces head and neck squamous cell cancer (HNSCC) growth and migration. Targeting GSK3 offers a promising therapeutic strategy for HNSCC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Head and neck squamous cell cancer (HNSCC) is a prevalent malignancy with a critical need for novel therapies.
  • Glycogen synthase kinase 3 (GSK3) has demonstrated varied roles in human cancers, acting as either a tumor suppressor or promoter.
  • Understanding GSK3's specific functions in HNSCC progression is essential for developing targeted treatments.

Purpose of the Study:

  • To investigate the role of glycogen synthase kinase 3 (GSK3) in the progression of head and neck squamous cell cancer (HNSCC).
  • To evaluate the effects of GSK3 inhibition on HNSCC cell viability, migration, and epithelial-mesenchymal transition (EMT).
  • To explore GSK3's influence on inflammatory cytokine expression in HNSCC.

Main Methods:

  • Analysis of baseline expression and activity of GSK3α/β using immunohistochemistry and western blotting.
  • Treatment of HNSCC cell lines with the GSK3α/β inhibitor SB 216763.
  • Assessment of cell viability (MTT assay), migration (xCELLigence), EMT markers (PCR Array), and inflammatory cytokine gene expression (Taqman probes).

Main Results:

  • GSK3α/β inhibition by SB 216763 resulted in dose-dependent reduction in HNSCC cell growth and migration.
  • Inhibition of GSK3α/β led to significant alterations in EMT markers and functional EMT dysregulation.
  • GSK3 differentially mediated the expression of TLR4- and TLR3-induced inflammatory cytokines in HNSCC, independent of NFkB activity.

Conclusions:

  • GSK3α/β is a critical regulator of proliferation and migration in HNSCC progression.
  • GSK3 plays a significant role in various regulatory networks governing HNSCC.
  • GSK3 represents a potential therapeutic target for clinical drug development in HNSCC.
Keywords:
GSK3HNSCC

More Related Videos

Progressive-ratio Responding for Palatable High-fat and High-sugar Food in Mice11:16

Progressive-ratio Responding for Palatable High-fat and High-sugar Food in Mice

Published on: May 3, 2012

22.8K
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.6K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.6K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
480
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K